GLP-1 RAs May Alter Thyroid Hormone Levels in Patients on Levothyroxine
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes and obesity, demonstrating significant metabolic benefits. Concurrently, millions of individuals manage hypothyroidism with daily levothyroxine replacement therapy, requiring careful monitoring of thyroid-stimulating hormone (TSH) levels to ensure optimal dosing. Despite the widespread use of both drug classes, there is a significant knowledge gap regarding how initiating GLP-1 RAs might impact TSH levels and levothyroxine requirements in patients already on stable thyroid hormone replacement.
Results
The study revealed significant alterations in TSH patterns following GLP-1 RA initiation. Patients starting GLP-1 RAs experienced a mean decrease in TSH levels by 23.5% (p<0.001) within 6 months compared to the control group, which showed no significant change. This reduction was sustained, with a 21.8% decrease observed at 12 months. A substantial 18.2% of patients initiating GLP-1 RAs required a reduction in their levothyroxine dose by an average of 12.5 mcg/day (p<0.001) to prevent iatrogenic hyperthyroidism, whereas only 3.1% of controls required a dose reduction. The effect was more pronounced in patients with higher baseline TSH levels (>4.0 mIU/L), who experienced a 35.1% average reduction in TSH (p<0.001). Furthermore, TSH testing frequency increased by 1.7-fold in the GLP-1 RA group during the first 3 months post-initiation.
Why It Matters
This study provides crucial real-world evidence suggesting that GLP-1 RA initiation significantly impacts TSH levels in patients on levothyroxine, often necessitating dose adjustments. The key implication is that clinicians should be aware of this interaction and consider more frequent TSH monitoring when starting patients on GLP-1 RAs who are already on thyroid hormone replacement. This finding could lead to updated clinical guidelines for managing hypothyroidism in patients receiving GLP-1 RAs, potentially preventing complications from over- or under-treatment. Future research should explore the underlying mechanisms of this interaction and validate these findings in prospective human trials.